Breaking News Instant updates and real-time market news.

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

21:39
11/14/18
11/14
21:39
11/14/18
21:39

Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald

Price target $10.

  • 27

    Nov

OVID Ovid Therapeutics
$4.75

-0.42 (-8.12%)

08/10/18
PIPR
08/10/18
NO CHANGE
Target $20
PIPR
Overweight
Piper sees value coming back into Ovid shares after pullback
Shares of Ovid Therapeutics have pulled back following the recent Angelman's data release, but investors underappreciate the exploratory nature of what was the first study of its kind, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, he believes the FDA will give flexibility in designing a registrational program for OV101 given the lack of treatments option and the significant unmet needs that exists for these patients. The analyst maintains an Overweight rating on Ovid with a $20 price target, believing share value will accrue as investors get a greater appreciation for the OV101 program and opportunity.
08/06/18
PIPR
08/06/18
NO CHANGE
Target $20
PIPR
Overweight
Ovid Therapeutics shares should recover from here, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren attributes Ovid Therapeutics' selloff to the lack of statistical significance on the domain-based endpoints in the Phase 2 STARS trial, but he believes the shares will recover from these levels as appreciation for the just-reported data grows and as the report of OV935 proof of concept dEE data near year-end approaches. The analyst, who thinks the dEE data has "exciting potential," keeps an Overweight rating and $20 price target on Ovid shares, which are down 35% to $6.20 in afternoon trading.
05/18/18
PIPR
05/18/18
INITIATION
Target $20
PIPR
Overweight
Ovid Therapeutics assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Ovid Therapeutics with an Overweight rating and $20 price target. The company is enrolling genetically-defined orphan populations with preclinical models that have demonstrated encouraging results, Van Buren tells investors in a research note.
04/20/18
LTCO
04/20/18
INITIATION
Target $27
LTCO
Buy
Ovid Therapeutics initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated Ovid Therapeutics with a Buy and $27 price target.

TODAY'S FREE FLY STORIES

TNDM

TNDM

07:24
09/18/19
09/18
07:24
09/18/19
07:24
Conference/Events
Tandem Diabetes management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Adobe analyst commentary  »

Adobe weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

GLW

Corning

$28.25

-1.79 (-5.96%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Corning analyst commentary  »

Corning shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNH

Syneos Health

$54.63

-0.77 (-1.39%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Conference/Events
Syneos Health management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

AXSM

Axsome Therapeutics

$28.17

-0.97 (-3.33%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Initiation
Axsome Therapeutics initiated  »

William Blair starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

SU

Suncor

$32.14

-0.31 (-0.96%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Conference/Events
Suncor management to meet with Morgan Stanley »

Refinery Tour with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NERV

Minerva

$8.09

-0.03 (-0.37%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Initiation
Minerva initiated  »

Minerva initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$138.86

1.25 (0.91%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Upgrade
Zimmer Biomet rating change  »

Zimmer Biomet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

07:20
09/18/19
09/18
07:20
09/18/19
07:20
General news
FX Update: The dollar traded moderately firmer »

FX Update: The dollar…

FDX

FedEx

07:19
09/18/19
09/18
07:19
09/18/19
07:19
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

MTDR

Matador

$17.10

-1.8 (-9.52%)

07:19
09/18/19
09/18
07:19
09/18/19
07:19
Initiation
Matador initiated  »

Matador initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

CBAY

CymaBay

$5.86

-0.02 (-0.34%)

07:17
09/18/19
09/18
07:17
09/18/19
07:17
Recommendations
CymaBay analyst commentary  »

CymaBay CMO change about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:14
09/18/19
09/18
07:14
09/18/19
07:14
Hot Stocks
BeyondSpring expects to submit NDAs for Plinabulin in U.S. in 2020 »

The following outlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

STAG

STAG Industrial

$29.71

-0.055 (-0.18%)

07:14
09/18/19
09/18
07:14
09/18/19
07:14
Conference/Events
STAG Industrial management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NBY

NovaBay

$0.53

0.0089 (1.72%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Initiation
NovaBay initiated  »

NovaBay initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

LECO

Lincoln Electric

$89.48

0.38 (0.43%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSC

Scansource

$30.64

-0.6 (-1.92%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Conference/Events
Scansource management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Hot Stocks
BeyondSpring sees sufficient cash to submit NDAs in China for Plinabulin »

As of June 30, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Earnings
BeyondSpring reports Q2 EPS (32c), one est. (27c) »

"During the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SBAC

SBA Communications

$252.94

6.55 (2.66%)

07:10
09/18/19
09/18
07:10
09/18/19
07:10
Conference/Events
SBA Communications management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:09
09/18/19
09/18
07:09
09/18/19
07:09
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

WLTW

Willis Towers Watson

$198.60

3.52 (1.80%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Hot Stocks
Willis Research Network partners with Mitiga Solutions on aviation initiative »

The Willis Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PM

Philip Morris

$71.98

-0.54 (-0.74%)

, MO

Altria Group

$41.31

-0.1 (-0.24%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Philip Morris, Altria Group analyst commentary  »

Philip Morris, Altria…

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.